Go Pro
→ How options let you do more with less capital (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$13.87
+0.5%		$14.17
$12.96
▼
$20.90
$292.72M0.7677,267 shs4,393 shs
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.20
+1.0%		$0.21
$0.18
▼
$0.40
$286.63M1.241.79 million shs467,385 shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$5.10
+0.2%		$5.42
$4.27
▼
$9.94
$308.59M0.641.56 million shs118,238 shs
Zomedica Corp. stock logo
ZOMDF
Zomedica
$0.08
-1.1%		$0.09
$0.06
▼
$0.16
$80.65M1.361.05 million shs229,794 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%+1.25%-1.92%-10.10%-8.06%
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.00%-0.85%+4.16%-30.62%-30.86%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.00%-6.26%-2.49%-13.44%+12.86%
Zomedica Corp. stock logo
ZOMDF
Zomedica
0.00%-2.00%-1.07%-12.33%-8.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$13.87
+0.5%		$14.17
$12.96
▼
$20.90
$292.72M0.7677,267 shs4,393 shs
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.20
+1.0%		$0.21
$0.18
▼
$0.40
$286.63M1.241.79 million shs467,385 shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$5.10
+0.2%		$5.42
$4.27
▼
$9.94
$308.59M0.641.56 million shs118,238 shs
Zomedica Corp. stock logo
ZOMDF
Zomedica
$0.08
-1.1%		$0.09
$0.06
▼
$0.16
$80.65M1.361.05 million shs229,794 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%+1.25%-1.92%-10.10%-8.06%
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.00%-0.85%+4.16%-30.62%-30.86%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.00%-6.26%-2.49%-13.44%+12.86%
Zomedica Corp. stock logo
ZOMDF
Zomedica
0.00%-2.00%-1.07%-12.33%-8.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.33
Sell$13.00-6.27% Downside
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.00
N/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
2.50
Moderate Buy$13.70168.68% Upside
Zomedica Corp. stock logo
ZOMDF
Zomedica
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ZOMDF, VNDA, AMRN, and CYDY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageUnderweight$13.00
8/17/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/10/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$21.00 ➝ $20.00
8/10/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$17.00 ➝ $12.00
7/17/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/16/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$213.65M1.37$0.36 per share38.23$22.07 per share0.63
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/A($0.08) per shareN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$216.10M1.43N/AN/A$5.54 per share0.92
Zomedica Corp. stock logo
ZOMDF
Zomedica
$32.03M2.52N/AN/A$0.12 per share0.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$38.80M-$0.99N/AN/AN/A-14.56%-0.20%-0.14%11/4/2026 (Estimated)
CytoDyn Inc. stock logo
CYDY
CytoDyn
-$42.70M-$0.02N/AN/AN/AN/AN/A-190.29%10/8/2026 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$220.47M-$4.63N/AN/AN/A-127.41%-49.81%-33.29%11/4/2026 (Estimated)
Zomedica Corp. stock logo
ZOMDF
Zomedica
-$81.86M-$0.01N/AN/AN/A-51.68%-16.82%-15.32%N/A

Latest ZOMDF, VNDA, AMRN, and CYDY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/8/2026Q1 2027
CytoDyn Inc. stock logo
CYDY
CytoDyn
-$0.05N/AN/AN/AN/AN/A
8/5/2026Q2 2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.5825-$1.04-$0.4575-$1.04$61.93 million$50.53 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
Zomedica Corp. stock logo
ZOMDF
Zomedica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.67
2.67
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A
0.26
0.26
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.01
1.61
1.60
Zomedica Corp. stock logo
ZOMDF
Zomedica
N/A
6.43
5.76

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
CytoDyn Inc. stock logo
CYDY
CytoDyn
5.06%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%
Zomedica Corp. stock logo
ZOMDF
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
4.21%
CytoDyn Inc. stock logo
CYDY
CytoDyn
1.00%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.70%
Zomedica Corp. stock logo
ZOMDF
Zomedica
6.75%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36021.12 million20.23 millionOptionable
CytoDyn Inc. stock logo
CYDY
CytoDyn
201.44 billion1.42 billionNot Optionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29060.46 million53.99 millionOptionable
Zomedica Corp. stock logo
ZOMDF
Zomedica
50979.95 million913.80 millionN/A

Recent News About These Companies

Zomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica's Marketing Engine: How Demand Becomes Revenue
September 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69531691-zomedica-corp-zomedica-announces-fourth-friday-at-four-webinar-on-september-25-2026-inside-zomedica-s-marketing-engine-how-demand-becomes-reven-200.htm
Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica’s Marketing Engine: How Demand Becomes Revenue
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zomedica-announces-fourth-friday-four-100000888.html
Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica's Marketing Engine: How Demand Becomes Revenue
September 9, 2026  |  accessnewswire.comA
Zomedica stock holds after Q2 2026 call
August 29, 2026  |  ad-hoc-news.deA
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
August 13, 2026  |  accessnewswire.comA
Zomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on August 28, 2026: Zomedica International: Building a Global Platform for Veterinary Innovation
August 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69274760-zomedica-corp-zomedica-announces-fourth-friday-at-four-webinar-on-august-28-2026-zomedica-international-building-a-global-platform-for-veterina-200.htm
Zomedica Announces "Fourth Friday at Four" Webinar on August 28, 2026: Zomedica International: Building a Global Platform for Veterinary Innovation
August 11, 2026  |  accessnewswire.comA
Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity
August 5, 2026  |  accessnewswire.comA
Zomedica Launches the PulseVet Acoustic Muffler(TM) Accessory for PulseVet(R) Shock Wave System
August 4, 2026  |  accessnewswire.comA
Zomedica Announces "Fourth Friday at Four" Webinar on July 24, 2026: Zomedica's Sales Organization - From Strategy to the Clinic
July 15, 2026  |  accessnewswire.comA
Zomedica's Assisi Loop(R) Products Designated "Fear Free(R)" as Alliance to Advance Low Stress Care and Pet Wellbeing Continues with Fear Free, LLC
June 25, 2026  |  accessnewswire.comA
Zomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on June 26, 2026: The Five Pillars of Zomedica - Framework for Clinical Value and Shareholder Returns
June 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68731615-zomedica-corp-zomedica-announces-fourth-friday-at-four-webinar-on-june-26-2026-the-five-pillars-of-zomedica-framework-for-clinical-value-and-s-200.htm
Zomedica Announces "Fourth Friday at Four" Webinar on June 26, 2026: The Five Pillars of Zomedica - Framework for Clinical Value and Shareholder Returns
June 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/zomedica-announces-fourth-friday-four-100000408.html
Zomedica Corp.: Zomedica's PulseVet System Repeats as Official Shock Wave of the United States Eventing Association
May 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68547079-zomedica-corp-zomedica-s-pulsevet-system-repeats-as-official-shock-wave-of-the-united-states-eventing-association-200.htm
Zomedica's PulseVet System Repeats as Official Shock Wave of the United States Eventing Association
May 20, 2026  |  accessnewswire.comA
Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech Market
May 14, 2026  |  accessnewswire.comA
Zomedica Corp Ordinary Shares ZOMDF
May 8, 2026  |  morningstar.comM
Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
May 6, 2026  |  accessnewswire.comA
Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
April 16, 2026  |  accessnewswire.comA
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
March 18, 2026  |  accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$13.87 +0.07 (+0.51%)
As of 11:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

CytoDyn stock logo

CytoDyn OTCMKTS:CYDY

$0.20 +0.00 (+1.01%)
As of 11:14 AM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$5.10 +0.01 (+0.18%)
As of 11:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Zomedica stock logo

Zomedica OTCMKTS:ZOMDF

$0.08 0.00 (-1.08%)
As of 11:14 AM Eastern

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas